Utility of serum β2‐microglobulin for prediction of kidney outcome among patients with biopsy‐proven diabetic nephropathy
Authors' conclusion
Among patients with biopsy-proven DN, serum β2-MG was an independent predictor of KFRT and improved prediction performance. In addition to serum creatinine, serum β2-MG should probably be measured for DN.
Study context
- Population
- Patients with biopsy-proven diabetic nephropathy at Nara Medical University Hospital99 developed kidney failure with replacement therapy (KFRT)
- Participants
- 408 patients
- Exposure
- Serum β2-MG level
- Outcome
- Kidney failure with replacement therapy (KFRT)
- Follow-up
- Median 6.7 years
Methodological detailssingle-centre, biopsy-proven, multivariable Cox and competing-risk regression
- Single-centre
- Biopsy-proven
- Multivariable Cox and competing-risk regression
Main finding
As reported in the abstract
KFRT per 1-unit increase in log-transformed serum β2-MG
HR, adjusted for clinical and histological risk factors
3.30
95% CI 1.57–6.94
Subdistribution HR, all-cause mortality as competing event
3.07
95% CI 1.55–6.06
Observational data: associations, not effects.
Further findings
Improvement in prediction of 5-year cumulative incidence of KFRT by adding log-transformed serum β2-MG
- Net reclassification improvement (NRI) (0.09-0.54)
- 0.32
- Integrated discrimination improvement (IDI) (0.01-0.56)
- 0.03
- Reduced Akaike information criterion (AIC)
Original publication
Utility of serum β2‐microglobulin for prediction of kidney outcome among patients with biopsy‐proven diabetic nephropathy. Diabetes Obes Metab. Published 3 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →